ICON has launched a new medical imaging solution tailored to the unique requirements of early phase trials. This new solution incorporates streamlined processes and procedures to maximize the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research, according to the company. Enhanced decision making is then enabled by MIRA, ICON’s image management system, which standardizes data from all imaging formats and allows for centralized analysis and interpretation of data.
ICON Medical Imaging’s early phase group will be led by Dr. James Conklin, senior vice president, Medical and Scientific Affairs, and Dr. Valerie Treyer, director, Medical and Scientific Affairs, who together have more than 45 years of experience in the management of medical image data used in clinical trials. The group will work closely with ICON Development Solutions.
“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” said Ted Gastineau, president, ICON Medical Imaging. “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”